Latest Tax Rebates News

International Graphite's March 2025 quarterly report highlights strong geopolitical tailwinds and government backing for its Springdale Graphite Project and Collie processing facilities, positioning the company as a key player in the critical minerals supply chain.

Empire Energy Group is advancing its Carpentaria-5H well hydraulic stimulation scheduled for June 2025, alongside preparations for the Carpentaria Gas Plant construction, aiming to commence gas sales from EP187 by late 2025 or early 2026.

Blue Energy has resolved a significant legal hurdle by securing an amended Environmental Authority for its Sapphire asset, enabling progression of the Petroleum Lease 1034 and continued pilot production testing despite operational interruptions.

Constellation Technologies Limited reports sustained sales growth and positive cash flow in Q3 2025, driven by its Callisto Food Safety & Compliance system and strategic market expansion.

EMVision Medical Devices has commenced the pivotal clinical trial for its emu™ bedside brain scanner aimed at FDA clearance, while advancing its First Responder device through successful aeromedical testing and ethics approvals. The company maintains strong cash reserves of $12.58 million to support ongoing innovation and clinical activities.

Identitii Limited advances its BNDRY platform with new agreements targeting hospitality and payments sectors, appoints Tim Phillipps as Executive Chair, and reports stable cash flow amid ongoing patent litigation.

Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.

Spacetalk Ltd has secured a $428,853 R&D tax rebate from the Australian Taxation Office, reinforcing its commitment to innovation while reporting a 16% increase in Annual Recurring Revenue and significant cost reductions.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.